ACER-002 BID

Phase 3Small molecule

AAcer Therapeutics Inc.

ACER-002 BID is one of 2 small molecule programs targeting Ehlers-Danlos syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ehlers-Danlos SyndromeRecruiting

Ehlers-Danlos SyndromePhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Ehlers-Danlos Syndrome

#DrugCompanyPhaseTrials

ACER-002 BID

AAcer Therapeutics Inc.

Phase 3

1 2

Riboflavin

CCornea and Laser Eye Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Ehlers-Danlos Syndrome

NCT05432466

Clinical

Trials by Indication[1]

Ehlers-Danlos syndrome1 trial

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

Recruiting·AAcer Therapeutics Inc.·Phase 3·NCT05432466·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACER-002 BID. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACER-002 BID compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACER-002 BID. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acer Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAcer Therapeutics Inc.

ACER-002 BID

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Ehlers-Danlos syndrome1 trial

References

Drug Info

Quick Facts

Related News